title: Tumor vaccines with dsRNA adjuvant ARNAX induces antigen-specific tumor shrinkage without cytokinemia.
abstract: Here, we introduce a double-stranded RNA mimic that is chemically synthesized to exclusively stimulate toll-like receptor 3 (TLR3). This function-defined TLR3 ligand, named ARNAX, acts as an adjuvant to induce antitumor CTL and NK without significant cytokinemia in mice, and thus superior to polyI:C for therapeutic vaccine immunotherapy against tumor.
authors.affiliation: Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University , Sapporo, Japan.
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Seya
authors.affiliation: Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University , Sapporo, Japan.
authors.forename: Yohei
authors.initials: Y
authors.lastname: Takeda
authors.affiliation: Department of Microbiology and Immunology, Graduate School of Medicine, Hokkaido University , Sapporo, Japan.
authors.forename: Misako
authors.initials: M
authors.lastname: Matsumoto
keywords: Antitumor CTL; Priming-phase adjuvant; no cytokine toxicity; tumor remission